Reported Saturday, Bristol Myers Squibb's KRAZATI Study Showed Noteworthy Progression-Free Survival In Phase 3 Study Of KRASG12C-Mutated Advanced NSCLC
Portfolio Pulse from Benzinga Newsdesk
Bristol Myers Squibb's KRAZATI showed significant improvement in progression-free survival in a Phase 3 study for KRASG12C-mutated advanced NSCLC, as presented at the 2024 ASCO Annual Meeting.
June 03, 2024 | 8:11 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Bristol Myers Squibb's KRAZATI demonstrated a statistically significant and clinically meaningful improvement in progression-free survival in a Phase 3 study for KRASG12C-mutated advanced NSCLC, as presented at the 2024 ASCO Annual Meeting.
The positive results from the Phase 3 KRYSTAL-12 study indicate a significant advancement in treatment for KRASG12C-mutated advanced NSCLC, which is likely to boost investor confidence and positively impact BMY's stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100